EcoDrugPlus

Glutamate Metabotropic Receptor 5

Ensembl ID : ENSKMAG00000007834
Gene Symbol: GRM5
3 Cross references
214 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSKMAG00000001376
Gene Symbol: LOC108250862
2 Cross references
249 Possible Orthologues:

Glutamate Receptor 1-Like

Ensembl ID : ENSKMAG00000017096
Gene Symbol: LOC108237968
3 Cross references
250 Possible Orthologues:

Glutamate Receptor 2-Like

Ensembl ID : ENSKMAG00000008124
Gene Symbol: LOC108246920
3 Cross references
242 Possible Orthologues:

Glutamate Receptor 3-Like

Ensembl ID : ENSKMAG00000012049
Gene Symbol: LOC108247597
3 Cross references
251 Possible Orthologues:

Glutamate Receptor 4

Ensembl ID : ENSKMAG00000008971
Gene Symbol: LOC108248150
3 Cross references
249 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 1

Ensembl ID : ENSKMAG00000015344
Gene Symbol: LOC108241403
3 Cross references
205 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2a-Like

Ensembl ID : ENSKMAG00000008300
Gene Symbol: LOC108240774
2 Cross references
98 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2b-Like

Ensembl ID : ENSKMAG00000021761
Gene Symbol: LOC108241544
3 Cross references
250 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSKMAG00000005582
Gene Symbol: LOC108235494
2 Cross references
212 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 2d-Like

Ensembl ID : ENSKMAG00000018820
Gene Symbol: LOC108242688
2 Cross references
214 Possible Orthologues:

Glutamate Receptor Ionotropic, Nmda 3a-Like

Ensembl ID : ENSKMAG00000012428
Gene Symbol: LOC108239047
2 Cross references
226 Possible Orthologues:


PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains. Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).

PREMIER has received funding from the Innovative Medicines Initiative 2 Joint Undertaking (JU) under grant agreement No 875508. The JU receives support from the EU’s Horizon 2020 research and innovation programme and the European Federation of Pharmaceutical Industries and Associations (EFPIA). The views reflect only the authors’ perspective and the JU is not responsible for any use that may be made of the information this manuscript contains.

Elements of the website have been developed under projects PREMIER and the Biocenter Finland Drug Discovery and Chemical Biology network. CSC-IT is thanked for providing computational resources. Content of the website is provided without guarantee for correctness. Data has been collected and integrated from multiple public sources, for the largest: FDA, HUGO Gene Nomenclature Committee, ChEMBL, IUPHAR/BPS guide to pharmacology, Reactome, UniProt, and Ensembl. Credit is given to Ensembl for collecting species images (provided under public domain licences such as Wikimedia and NHGRI).